<p><strong>Hims &amp; Hers Health Inc. NYSE: HIMS</strong> 的股票在最近幾周引起了轟動，達到了每股近 73 美元的新歷史高點。然而，幾天後，大部分漲幅又迅速回落，跌至每股低至 36 美元。現在，這正是大多數投資者會放棄並忘記他們最初為何購買該股票的時刻。</p>
<p>這沒關係；在經歷如此劇烈的下跌後，人們仍然相信公司的故事是人之常情。然而，市場向這些近期賣出股票的投資者展示了，仍然有一些合理的理由讓投資者繼續持有 Hims &amp; Hers 的股票，長期來看。</p>
<p>獲取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
<p>這一假設可以通過股票從上週觸及的低點反彈高達 24% 來得出，這給市場一個理由認為底部可能已經形成。</p>
<p>即使在這種潛在的復甦過程中，對於那些最近可能失去 Hims &amp; Hers 收益的投資者來説，情緒仍然偏向於報復，因此今天可能需要其他觀點。假設這是在改善醫療行業的科技股中普遍存在的情緒，那麼 <strong>Clover Health Investments Inc. NASDAQ: CLOV</strong> 有明確的路徑可以像 Hims &amp; Hers 在回調前那樣起飛。</p>
<h2><strong>價格走勢更有利於 Clover 而非 Hims &amp; Hers 股票</strong></h2>
<p>如果價格走勢和表現能反映市場對股票的整體感覺，投資者可以關注今天 Hims &amp; Hers 和 Clover 的交易情況。</p>
<p>考慮到 Clover 目前處於其 52 周高點的 82%，而 Hims &amp; Hers 僅為 62%，投資者可以在某種程度上假設市場現在更青睞 Clover。</p>
<p>但這種價格走勢僅僅是開始，因為公司必須有其他基本因素來證明其當前的交易合理性。其中一個可能是華爾街對 Clover 每股收益（EPS）的當前預測，預計在 2025 年第二季度約為 0.03 美元。</p>
<p>這意味着與今天每股淨虧損 0.02 美元相比，存在顯著的躍升。考慮到股票價格通常由潛在的 EPS 增長驅動，這可能為 Clover 開闢了一條真正起飛的道路，類似於 Hims &amp; Hers 在今年早些時候的表現。</p>
<p>不過，還有其他基本利好因素在起作用，例如公司最新季度財報中看到的關鍵績效指標（KPI）。第一個指標可以在平均醫療保險優勢會員的年增長 30% 中看到。</p>
<p>基於會員的增長，投資者可以看到 Clover 報告的保險收入高達 3.307 億美元，比去年同期增長 9.1%。</p>
<p>隨着增長率朝這個方向發展，華爾街分析師對公司在未來幾個月實現淨盈利感到如此自信是有道理的。</p>
<h2><strong>Clover 股票還有多少上漲空間？</strong></h2>
<p>根據華爾街分析師的共識價格目標，Clover 股票今天的合理估值定為每股 5.0 美元。這不僅意味着新的 52 周高點，還意味着從當前交易價格上漲高達 26% 的潛力，為投資者在今天的佈局中提供了足夠的看漲空間。</p>
<p>考慮到華爾街對估值和 EPS 預測的看法，投資者看到先鋒集團的配置者在 2025 年 2 月將其在 Clover 股票中的持股增加至 2.0% 也就不足為奇了。</p>
<p>從百分比上看，這可能聽起來不算多。然而，這確實使他們的淨頭寸今天達到了 6170 萬美元，或佔公司 3.9% 的股份。</p>
<p>在這次近期購買中，還有一個重要因素需要考慮。這些配置者願意為 Clover 股票支付高達 6.6 倍的市淨率（P/B），高於醫療服務計劃行業今天 4.9 倍的平均 P/B。</p>
<p>有人會認為這隻股票相對於其同行來説價格昂貴。然而，經驗豐富的交易者會提醒他們，市場總是願意為他們認為有能力超越同行和整體市場的股票支付溢價，這在今天的 Clover 中似乎是一個合理的案例。</p>
<h2>你現在應該投資 1000 美元在 Hims &amp; Hers Health 嗎？</h2>
<p>在考慮 Hims &amp; Hers Health 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Hims &amp; Hers Health 並不在名單上。</p>
<p>雖然 Hims &amp; Hers Health 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

HIMS

三葉草健康

<p>Clover Health Investments Inc.（納斯達克代碼：CLOV）可能在 Hims & Hers Health Inc.（紐約證券交易所代碼：HIMS）最近的反彈後迎來增長。Hims & Hers 的股價在經歷了大幅下跌後，最近反彈了 24%，而 Clover 的交易價格為其 52 周高點的 82%。分析師預測，Clover 的每股收益將在 2025 年第二季度顯著上升，這得益於醫療保險優勢會員增長 30% 和保險收入增長 9.1%。在共識目標價為 5.00 美元的情況下，Clover 可能會有 26% 的上漲空間，儘管其市淨率高於同行，但仍吸引了投資者的關注</p>

<p>Shares of <strong>Hims &amp; Hers Health Inc. NYSE: HIMS</strong> have made a splash in recent weeks, reaching a new all-time high of just under $73 per share. However, a few days later, most of the upside moved right back, crashing down to as low as $36 per share. Now, this is where most investors would throw in the towel and forget why they bought the stock in the first place.</p>
<div class="lb-trans"><p><strong>Hims &amp; Hers Health Inc. NYSE: HIMS</strong> 的股票在最近幾周引起了轟動，達到了每股近 73 美元的新歷史高點。然而，幾天後，大部分漲幅又迅速回落，跌至每股低至 36 美元。現在，這正是大多數投資者會放棄並忘記他們最初為何購買該股票的時刻。</p>
</div><p>This is alright; it’s human nature to still be convinced about a company’s story after such a steep decline. However, the market has shown these recent sellers that there are still some valid reasons for investors to keep hanging on to their shares of Hims &amp; Hers stock for the long haul.</p>
<div class="lb-trans"><p>這沒關係；在經歷如此劇烈的下跌後，人們仍然相信公司的故事是人之常情。然而，市場向這些近期賣出股票的投資者展示了，仍然有一些合理的理由讓投資者繼續持有 Hims &amp; Hers 的股票，長期來看。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
</div><p>This assumption can be made by the way that the stock bounced back by as much as 24% from the lows hit last week, giving markets a reason to think that the bottom could be in now.</p>
<div class="lb-trans"><p>這一假設可以通過股票從上週觸及的低點反彈高達 24% 來得出，這給市場一個理由認為底部可能已經形成。</p>
</div><p>Even with this potential recovery underway, the sentiment is still on the vengeful side of the spectrum for investors who potentially lost their gains in Hims &amp; Hers recently, so alternative views may be needed today. Assuming that this is the sentiment across the board in the technology stocks that improve the medical sector, there’s a clear path for <strong>Clover Health Investments Inc. NASDAQ: CLOV</strong> to take off just the way Hims &amp; Hers did before the pullback.</p>
<div class="lb-trans"><p>即使在這種潛在的復甦過程中，對於那些最近可能失去 Hims &amp; Hers 收益的投資者來説，情緒仍然偏向於報復，因此今天可能需要其他觀點。假設這是在改善醫療行業的科技股中普遍存在的情緒，那麼 <strong>Clover Health Investments Inc. NASDAQ: CLOV</strong> 有明確的路徑可以像 Hims &amp; Hers 在回調前那樣起飛。</p>
</div><h2><strong>Price Action Favors Clover Over Hims &amp; Hers Stock</strong></h2>
<div class="lb-trans"><h2><strong>價格走勢更有利於 Clover 而非 Hims &amp; Hers 股票</strong></h2>
</div><p>If price action and performance are any indication of how the market overall feels about a stock, investors can look to where both Hims &amp; Hers and Clover are trading today.</p>
<div class="lb-trans"><p>如果價格走勢和表現能反映市場對股票的整體感覺，投資者可以關注今天 Hims &amp; Hers 和 Clover 的交易情況。</p>
</div><p>Given that Clover is now sitting at 82% of its 52-week high, compared to only 62% for Hims &amp; Hers, investors could somewhat assume that the market now favors Clover.</p>
<div class="lb-trans"><p>考慮到 Clover 目前處於其 52 周高點的 82%，而 Hims &amp; Hers 僅為 62%，投資者可以在某種程度上假設市場現在更青睞 Clover。</p>
</div><p>But this price action is only the beginning, as there must be other fundamental factors at play for the company to justify its current trading. One could be the current Wall Street forecasts for earnings per share (EPS) in Clover, which hover around $0.03 for the second quarter of 2025.</p>
<div class="lb-trans"><p>但這種價格走勢僅僅是開始，因為公司必須有其他基本因素來證明其當前的交易合理性。其中一個可能是華爾街對 Clover 每股收益（EPS）的當前預測，預計在 2025 年第二季度約為 0.03 美元。</p>
</div><p>This implies a significant jump from today’s net loss of $0.02 per share. Given that stock prices are typically driven by underlying EPS growth, this could open up a path for Clover to really take off in a similar manner to which Hims &amp; Hers did earlier this year.</p>
<div class="lb-trans"><p>這意味着與今天每股淨虧損 0.02 美元相比，存在顯著的躍升。考慮到股票價格通常由潛在的 EPS 增長驅動，這可能為 Clover 開闢了一條真正起飛的道路，類似於 Hims &amp; Hers 在今年早些時候的表現。</p>
</div><p>Other fundamental tailwinds are at play, though, such as the key performance indicators (KPIs) seen in the company’s latest quarterly earnings presentation. The first one of these indicators could be seen in the 30% annual growth in the average Medicare Advantage memberships.</p>
<div class="lb-trans"><p>不過，還有其他基本利好因素在起作用，例如公司最新季度財報中看到的關鍵績效指標（KPI）。第一個指標可以在平均醫療保險優勢會員的年增長 30% 中看到。</p>
</div><p>Based on this jump in memberships, investors can see how Clover reported up to $330.7 million of insurance revenue, a 9.1% growth rate from the same quarter in the previous year.</p>
<div class="lb-trans"><p>基於會員的增長，投資者可以看到 Clover 報告的保險收入高達 3.307 億美元，比去年同期增長 9.1%。</p>
</div><p>With growth rates headed this way, it would make sense for Wall Street analysts to feel this confident about the company hitting net profitability in the coming months.</p>
<div class="lb-trans"><p>隨着增長率朝這個方向發展，華爾街分析師對公司在未來幾個月實現淨盈利感到如此自信是有道理的。</p>
</div><h2><strong>But How Much Upside Is There For Clover Stock?</strong></h2>
<div class="lb-trans"><h2><strong>Clover 股票還有多少上漲空間？</strong></h2>
</div><p>Well, according to the consensus price target from Wall Street analysts, Clover stock’s fair valuation is set for $5.0 a share today. This calls for not only a new 52-week high but also a rally of up to 26% from where it trades today, proposing enough bullish upside for investors to consider in today’s setup.</p>
<div class="lb-trans"><p>根據華爾街分析師的共識價格目標，Clover 股票今天的合理估值定為每股 5.0 美元。這不僅意味着新的 52 周高點，還意味着從當前交易價格上漲高達 26% 的潛力，為投資者在今天的佈局中提供了足夠的看漲空間。</p>
</div><p>Considering this view on valuations and EPS forecasts from Wall Street, it shouldn’t be a surprise for investors to see allocators from the Vanguard Group boost their holdings in Clover stock by up to 2.0% as of February 2025.</p>
<div class="lb-trans"><p>考慮到華爾街對估值和 EPS 預測的看法，投資者看到先鋒集團的配置者在 2025 年 2 月將其在 Clover 股票中的持股增加至 2.0% 也就不足為奇了。</p>
</div><p>This may not sound like much on a percentage basis. Still, it did bring their net position to a high of $61.7 million today, or 3.9% ownership in the company.</p>
<div class="lb-trans"><p>從百分比上看，這可能聽起來不算多。然而，這確實使他們的淨頭寸今天達到了 6170 萬美元，或佔公司 3.9% 的股份。</p>
</div><p>Here’s an essential factor to consider in this recent purchase as well. These allocators were willing to pay up to 6.6x in price-to-book (P/B) for Clover stock today, a premium above the medical service plans industry’s 4.9x average P/B today.</p>
<div class="lb-trans"><p>在這次近期購買中，還有一個重要因素需要考慮。這些配置者願意為 Clover 股票支付高達 6.6 倍的市淨率（P/B），高於醫療服務計劃行業今天 4.9 倍的平均 P/B。</p>
</div><p>Some would call this stock expensive next to its peers. However, seasoned traders would remind them that the market will always be ready to pay a premium for stocks that they believe have what it takes to outperform the peer group and the overall market, which seems to be a justifiable case in Clover today.</p>
<div class="lb-trans"><p>有人會認為這隻股票相對於其同行來説價格昂貴。然而，經驗豐富的交易者會提醒他們，市場總是願意為他們認為有能力超越同行和整體市場的股票支付溢價，這在今天的 Clover 中似乎是一個合理的案例。</p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Hims &amp; Hers Health 嗎？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Hims &amp; Hers Health 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Hims &amp; Hers Health 並不在名單上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Hims &amp; Hers Health 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

錯過了 Hims & Hers Health 的反彈？三葉草健康可能是下一個